Today, Alexion’s first complement inhibitor is now approved for four indications, spanning hematology, nephrology, and neurology, and the company has obtained approval of a second complement ...

Alexion and Complement Pharma announce partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders.

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent ...

At first, the scientific community was skeptical about complement inhibition — targeting specific parts of the complement cascade to prevent the destruction of cells — speculating that it ...